166 related articles for article (PubMed ID: 37803838)
21. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H; Zhang Y; Yu S; Du X; Xu N; Shao R; Lin D; Chen Y; Xiao J; Sun Z; Deng L; Liang X; Zhang H; Guo Z; Dai M; Shi P; Huang F; Fan Z; Yin Z; Xuan L; Lin R; Jiang X; Yu G; Liu Q
J Hematol Oncol; 2023 Apr; 16(1):42. PubMed ID: 37120593
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
23. [Safety and the Short-Term Efficacy of Venetoclax Combined with Azacitidine Followed by Cladribine in Children with Refractory/Relapsed Acute Myeloid Leukemia].
DU WW; Liu SX; Wang Y; He HL; Guo AL; Hu SY; Lu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1635-1638. PubMed ID: 38071039
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C; Ram R; Gural A; Wolach O; Gino-Moor S; Vainstein V; Nachmias B; Apel A; Koren-Michowitz M; Pasvolsky O; Yerushalmi R; Danylesko I; Cohen Y; Peretz G; Moshe Y; Zektser M; Yeganeh S; Rowe JM; Ofran Y
Leuk Lymphoma; 2020 Sep; 61(9):2221-2225. PubMed ID: 32420775
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
27. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia.
Ravindra A; Acharya L; Loeffler B; Mott S; Sutamtewagul G; Dhakal P
Leuk Res; 2023 Dec; 135():107407. PubMed ID: 37925761
[TBL] [Abstract][Full Text] [Related]
30. [Venetoclax Combined with CACAG Regimen in the Treatment of Patients with Refractory/Relapse Acute Myeloid Leukemia: A Prospective Clinical Study].
Gao WJ; Yang JJ; Li M; Wen YN; Jiao YF; LE N; Liu YC; Wang N; Huang S; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):90-95. PubMed ID: 38387905
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
[No Abstract] [Full Text] [Related]
33. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
35. Short-course Venetoclax With Standard Chemotherapy Is Effective in Early T-cell Precursor Acute Lymphoblastic Leukemia.
Borah P; Dayal N; Pathak S; Naithani R
J Pediatr Hematol Oncol; 2023 Jul; 45(5):271-274. PubMed ID: 37027330
[TBL] [Abstract][Full Text] [Related]
36. Case report: Treatment of two cases of recurrent/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen.
Jiang Y; Ji L; Jin X; Wu H; He M; Shen F; Xu X; Jiang H
Front Med (Lausanne); 2024; 11():1358161. PubMed ID: 38523911
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
Canaani J; Frisch A; Pollyea DA; Schwartz M; Aumann S; Ganzel C; Haran A; Even-Zohar NG; Shaulov A; Vainstein V; Moshe Y; Ofran Y; Wolach O; Nachmias B
Eur J Haematol; 2023 Sep; 111(3):365-372. PubMed ID: 37254665
[TBL] [Abstract][Full Text] [Related]
38. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
[TBL] [Abstract][Full Text] [Related]
39. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
40. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
